account_balance
Investment manager · 13F filer · SEC CIK 1777015
Parkman Healthcare Partners LLC
Reported value$974Mas of Jun 30, 2026
Positions76 17 new, 30 sold out
Top 10 weight33.6%MBX alone is 5%
FiledAug 1445 days after quarter end
Portfolio · as of Jun 30, 2026
Where the money is
New or addedTrimmedHeld
MBXMBX Biosciences Inc
4.5%
LLYEli Lilly & Co
4.3%
CVSCVS Health Corp
4.2%
DXCMDexcom Inc
3.7%Trimmed −22%
PTCTPTC Therapeutics Inc
3.6%
RCUSArcus Biosciences Inc
2.9%Trimmed −24%
GPCRStructure Therapeutics Inc
2.7%Added +109%
VRDNViridian Therapeutics Inc
2.6%Added +147%
AGIOAgios Pharmaceuticals Inc
2.5%Added +66%
INBXInhibrx Biosciences Inc
2.5%New
XENEXenon Pharmaceuticals Inc
2.5%Trimmed −20%
EWTXEdgewise Therapeutics Inc
2.4%Added +79%
MBX4.5%LLY4.3%CVS4.2%DXCM3.7%PTCT3.6%
RCUSArcus Biosciences Inc
2.9%Trimmed −24%
GPCR2.7%VRDN2.6%AGIO2.5%INBX2.5%XENE2.5%EWTX2.4%Boxes show the top 12 stocks, sized against each other. The bar above shows how much of the fund they are. 13F only covers US-listed stocks, so foreign holdings and short positions are missing.
Show the top 12 as a list
MBX MBX Biosciences Inc 4.5% HeldLLY Eli Lilly & Co 4.3% HeldCVS CVS Health Corp 4.2% HeldDXCM Dexcom Inc 3.7% Trimmed −22%PTCT PTC Therapeutics Inc 3.6% HeldRCUS Arcus Biosciences Inc 2.9% Trimmed −24%GPCR Structure Therapeutics Inc 2.7% Added +109%VRDN Viridian Therapeutics Inc 2.6% Added +147%AGIO Agios Pharmaceuticals Inc 2.5% Added +66%INBX Inhibrx Biosciences Inc 2.5% NewXENE Xenon Pharmaceuticals Inc 2.5% Trimmed −20%EWTX Edgewise Therapeutics Inc 2.4% Added +79%
What changed